Go Pro
LON:GENF

Genflow Biosciences Interim Earnings Report

Genflow Biosciences logo
GBX 1.94 +0.06 (+3.20%)
As of 08:20 AM Eastern

Genflow Biosciences EPS Results

Actual EPS
-GBX 0.19
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Genflow Biosciences Revenue Results

Actual Revenue
N/A
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Genflow Biosciences Announcement Details

Quarter
Interim
Time
Before Market Opens
Conference Call Date
N/A
Conference Call Time
N/A

Conference Call Resources

Genflow Biosciences Earnings Headlines

SIRT6 gene therapy shows promise in aged dogs - ICYMI
NASA's ISS Replacement Could Go to This Tiny Space Firm
NASA has commissioned SpaceX to decommission the $150 billion International Space Station, but the contract to build its replacement is reportedly headed to a tiny firm a fraction of SpaceX's size, one NASA has quietly funded for five years. History shows these NASA announcements can move fast: Intuitive Machines jumped 66% in a day, Momentus soared 155%, and Sidus Space climbed 180% after landing subcontractor roles.tc pixel
Genflow Biosciences PLC Announces Notice of AGM
See More Genflow Biosciences Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Genflow Biosciences? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Genflow Biosciences and other key companies, straight to your email.

About Genflow Biosciences

Genflow Biosciences (LON:GENF) is a UK based biotech company with R&D facilities in Belgium and a US office in Cambridge, MA, driven by one mission: to deliver therapeutics that potentially halt or slow the ageing process in humans and dogs. The company’s lead compound works through the delivery of a centenarian variant of the SIRT6 gene and has yielded promising preclinical results.

View Genflow Biosciences Profile